Akademik Veri Yönetim Sistemi
9th International BAU Drug Design Congress, 2023, İstanbul, Türkiye, 29 Kasım - 02 Aralık 2023
Introduction: Psoriasis, a chronic multifactorial skin disease, is characterized by hyperproliferation and abnormal differentiation of epidermal keratinocytes. Current therapeutics for psoriasis have limited efficacy and tolerability, thus alternative agents are needed. Astragaloside-IV (AS-IV) is a herbal compound that is widely used in Chinese medicine. Recently, AS-IV has been shown to prevent UVB-induced oxidative damage and inflammatory response in HaCaT cells, however its effect in psoriasis is unknown. HaCaT cells gain hyperproliferative properties when treated with lipopolysaccharide (LPS) and this is commonly used as an in vitro model of psoriasis. We investigated the effect of AS-IV on LPSinduced proliferation of HaCaT cells.
Method: HaCaT cells were incubated with LPS (100 ng/ml) and AS-IV (12,5-25-50-100 µM) or vehicle (DMEM, as control). Cell proliferation was measured with WST-1 colorimetric assay.
Results: Proliferation was significantly reduced (p<0.05) in LPS-treated HaCaT cells cotreated with 12.5 and 25 µM AS-IV compared to vehicle. In contrast, in non-LPS-treated cells, 50 µM AS-IV increased proliferation (p<0.05) compared to vehicle.
Conclusion: AS-IV demonstrated a significant concentration- dependent antiproliferative
effect only in HaCaT cells treated with LPS. Role of cytokines (such as IL-1β, IL-6) in the
mechanism of action of AS-IV is currently under investigation. Future studies involving animal
models will pave the way for development of AS-IV as a new therapeutic agent in psoriasis.
This study was supported by the TUBITAK 2209A University Students Domestic Research
Projects Support Program (Project no 1919B012111805 to AB).
Key words: therapeutic, astragaloside, LPS, proliferation.